TY - CHAP
T1 - Update of the prostate, lung, colorectal, and ovarian cancer screening trial
AU - Andriole, Gerald L.
PY - 2014
Y1 - 2014
N2 - The prostate portion of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial began in the early 1990s to assess the ability of annual PSA and DRE to reduce prostate cancer specific mortality in men aged 55-74. Approximately 80,000 men have been randomized and followed for a minimum of 13 years. Thus far, annual screening in this study has not been associated with a reduction of prostate cancer specific mortality. The potential explanations for this finding are reviewed.
AB - The prostate portion of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial began in the early 1990s to assess the ability of annual PSA and DRE to reduce prostate cancer specific mortality in men aged 55-74. Approximately 80,000 men have been randomized and followed for a minimum of 13 years. Thus far, annual screening in this study has not been associated with a reduction of prostate cancer specific mortality. The potential explanations for this finding are reviewed.
UR - http://www.scopus.com/inward/record.url?scp=84958553552&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-45195-9_6
DO - 10.1007/978-3-642-45195-9_6
M3 - Chapter
C2 - 24531777
AN - SCOPUS:84958553552
SN - 9783642451942
T3 - Recent Results in Cancer Research
SP - 53
EP - 57
BT - Prostate Cancer Prevention
PB - Springer New York LLC
ER -